“ THE INVESTMENT FROM WVJIT IS CRITICAL FOR PROGRESSING THE TECHNOLOGIES TOWARDS COMMERCIALIZATION”
SPECIAL ADVERTISING SECTION whose indications are uveal melanoma and cutaneous melanoma; and MTI- 301 targets SCD-1, whose indications are triple negative breast cancer, hepatocellular carcinoma— one of the fastest growing cancer indicators in the state— nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
With the addition of WVCAP funding, Modulation Therapeutics will now be able to complete two Phase I clinical trials and initiate the Phase II trials for its MTI-201 and MTI-301 therapies. The Phase I clinical trial for MTI-201 is already
With investment from WVU Medicine supporting the company as well, Hazlehurst says the company is on track for long-term success.
“ We anticipate the investment will be the catalyst to continued development and investment into the company,” she says.“ We believe it is the cornerstone to ensure FDA approval of MTI-201 and MTI-301.”
In Morgantown, Modulation Therapeutics has enlisted the work of two local Ph. D.- level research scientists to assist in its
its connections with local service providers, business ventures and potential investors. She explains that with the JIT investment, the company is enabled to contribute to local economic growth and further showcase the benefits and potential for West Virginia’ s emerging biotech sector.
“ The WVJIT partnership will allow for input with a broader depth of experience and perspective as the company continues to grow and develop novel therapies for the treatment of cancer and chronic liver disease,” Hazlehurst says.
“ THE INVESTMENT FROM WVJIT IS CRITICAL FOR PROGRESSING THE TECHNOLOGIES TOWARDS COMMERCIALIZATION”
nearing completion, while Phase II is in the design process. The Phase I clinical trial for MTI-301 targets SCD1 and lipid metabolism for cancer treatment and is open for enrollment.
“ The investment from WVJIT is critical for progressing the technologies towards commercialization,” Hazlehurst says.“ If this funding was not available, the company would be on pause. This is especially true as the NIH SBIR / STTR program awaits reauthorization from Congress.”
Previously, Modulation Therapeutics worked with partners at WVU to secure STTR funding as well as collaborated with members of the WVU Cancer Institute. Currently, the company collaborates with the WVU Health Sciences Center for testing technologies and is in talks with the cancer institute t o begin clinical trials for its MTI-201 and MTI-301 programs. operations as well as engaged with local service providers such as accountants and insurance agents to aid in the company’ s logistics. Through initiatives like these, the company has become a welcome asset to the Morgantown community, most importantly by providing access to cancer and liver disease patients in West Virginia to groundbreaking therapeutic options.
Hazlehurst says the company anticipates that continued work with WVJIT will allow the company to further solidify
Modulation Therapeutics is committed to expanding treatment options for patients who need them most by advancing its clinical programs and further establishing its partnerships within the state. By helping grow the biotech landscape in Morgantown and throughout West Virginia, the company is a major benefit to public health and the local economy.
“ We anticipate that moving forward the unique infrastructure and expertise of WVU Medicine and WVU Cancer Institute will be a critical partner for success in navigating enrollment of patients in future clinical trials.”
PROUDLY SPONSORED BY WVJIT | 304-205-8185 | WVJITInfo @ wv. gov